Role of Sodium-Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
January 2025
in “
touchREVIEWS in Endocrinology
”
TLDR SGLT2 inhibitors may help manage PCOS symptoms effectively.
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) show promise as a therapy for managing polycystic ovary syndrome (PCOS) by improving metabolic and hormonal parameters. These inhibitors can be used alone or in combination with metformin or glucagon-like peptide-1 receptor agonists (GLP1RA), suggesting a versatile approach to treatment. The review highlights the potential of SGLT2i in addressing the complex symptoms associated with PCOS, offering a new avenue for therapeutic intervention.